Goal and Learning Outcomes

Upon successful completion of this activity, you should be better prepared to:

  • Determine clinical signs and testing approaches to facilitate LC-FAOD diagnosis
  • Explain the mechanistic rationale that underlies the application of new approved therapy for the treatment of LC-FAOD
  • Evaluate data regarding the safety and efficacy results from clinical trials that evaluate current treatment strategies among patients with LC-FAOD
  • Describe the clinical importance of recent trial findings in the context of evolving treatment standards in the field of LC-FAOD management


Barbara K. Burton, MD

Professor of Pediatrics, Division of Genetics, Birth Defects and Metabolism
Ann & Robert H. Lurie Children’s Hospital
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Jerry Vockley, MD, PhD

Professor of Human Genetics
University of Pittsburgh
Chief of Medical Genetics
Director of the Center for Rare Disease Therapy
UPMC Children's Hospital of Pittsburgh
Cleveland Family Endowed Chair in Pediatric Research
Pittsburgh, PA